top of page

Research & Development Pipeline

RS Oncology’s development pipeline was initiated in early 2022 with the phase 1/2 MITOPE clinical trial

RSO-021

Local intrapleural administration via a catheter

Malignant Pleural Mesothelioma

Malignant Cancers with Pleural Effusion

MITOPE-CLINICAL.png

Breast

Ovarian

NSCLC

RSO-023

Intraperitoneal Administration

Solid Tumors

TBD

Single Agent Meso with MPE 2nd or beyond

 Single Agent all solid tumors with MPE 2nd or beyond

RSO-021 window of opportunity meso

RSO-021 + Paclitaxel in lung with MPE in 2nd or beyond

RSO-024

Systemic Treatment

Solid Tumors

Liquid Tumors

TBD

RSO-025

Topical Therapy

Melanoma
TBD

bottom of page